Pathophysiological mechanisms and clinical evidence of relationship between Nonalcoholic fatty liver disease (NAFLD) and cardiovascular disease
2021-01-01 Caturano, A.; Galiero, R.; Vetrano, E.; Cesaro, A.; Rinaldi, L.; Salvatore, T.; Marfella, R.; Sardu, C.; Moscarella, E.; Gragnano, F.; Calabro, P.; Sasso, F. C.
The Diabetic Cardiomyopathy: The Contributing Pathophysiological Mechanisms
2021-01-01 Salvatore, T.; Pafundi, P. C.; Galiero, R.; Albanese, G.; Di Martino, A.; Caturano, A.; Vetrano, E.; Rinaldi, L.; Sasso, F. C.
The prognostic role of interatrial block among COVID-19 patients hospitalized in medicine wards
2022-01-01 Russo, V.; Albani, S.; Caturano, A.; Weisz, S. H.; Parisi, V.; Conte, M.; Zaccaro, L.; D'Andrea, A.; Al-Turky, A.; Marchel, M.; Marano, M.; Sasso, F. C.; Attena, E.
Diabetic Gastroparesis: Navigating Pathophysiology and Nutritional Interventions
2024-01-01 Caturano, A.; Cavallo, M.; Nilo, D.; Vaudo, G.; Russo, V.; Galiero, R.; Rinaldi, L.; Marfella, R.; Monda, M.; Luca, G.; Sasso, F. C.
Polypharmacy and Major Adverse Events in Atrial Fibrillation
2022-01-01 Caturano, A.; Spiezia, S.; Brunelli, V.; Galiero, R.; Sasso, F. C.
Pharmacogenomics of Cardiovascular Drugs for Atherothrombotic, Thromboembolic and Atherosclerotic Risk
2023-01-01 Mauriello, A.; Ascrizzi, A.; Molinari, R.; Falco, L.; Caturano, A.; D'Andrea, A.; Russo, V.
Can metformin exert as an active drug on endothelial dysfunction in diabetic subjects?
2021-01-01 Salvatore, T.; Pafundi, P. C.; Galiero, R.; Rinaldi, L.; Caturano, A.; Vetrano, E.; Aprea, C.; Albanese, G.; Di Martino, A.; Ricozzi, C.; Imbriani, S.; Sasso, F. C.
An Overview of the Cardiorenal Protective Mechanisms of SGLT2 Inhibitors
2022-01-01 Salvatore, T.; Galiero, R.; Caturano, A.; Rinaldi, L.; Di Martino, A.; Albanese, G.; Di Salvo, J.; Epifani, R.; Marfella, R.; Docimo, G.; Lettieri, M.; Sardu, C.; Carlo Sasso, F.
Impact of sglt2 inhibitors on heart failure: From pathophysiology to clinical effects
2021-01-01 Palmiero, G.; Cesaro, A.; Vetrano, E.; Pafundi, P. C.; Galiero, R.; Caturano, A.; Moscarella, E.; Gragnano, F.; Salvatore, T.; Rinaldi, L.; Calabro, P.; Sasso, F. C.
Dysregulated Epicardial Adipose Tissue as a Risk Factor and Potential Therapeutic Target of Heart Failure with Preserved Ejection Fraction in Diabetes
2022-01-01 Salvatore, T.; Galiero, R.; Caturano, A.; Vetrano, E.; Rinaldi, L.; Coviello, F.; Di Martino, A.; Albanese, G.; Colantuoni, S.; Medicamento, G.; Marfella, R.; Sardu, C.; Sasso, F. C.
Comment on: Prevalence of micro and macro vascular complications and their risk factors in type 2 diabetes in saudi arabian population: An analysis from shis
2021-01-01 Caturano, A.; Mercadante, S.; Mariniello, A.; Esposito, F.; Galiero, R.; Brunelli, V.
Cardiac Hypertrophy: From Pathophysiological Mechanisms to Heart Failure Development
2022-01-01 Caturano, A.; Vetrano, E.; Galiero, R.; Salvatore, T.; Docimo, G.; Epifani, R.; Alfano, M.; Sardu, C.; Marfella, R.; Rinaldi, L.; Sasso, F. C.
The Significance of Statin-Associated Muscle Symptoms and Its Impact on Patient Adherence and Outcomes
2023-01-01 Caturano, A.; Albanese, G.; Di Martino, A.; Galiero, R.; Sasso, F. C.
Effects of a Combination of Empagliflozin Plus Metformin vs. Metformin Monotherapy on NAFLD Progression in Type 2 Diabetes: The IMAGIN Pilot Study
2023-01-01 Caturano, A.; Galiero, R.; Loffredo, G.; Vetrano, E.; Medicamento, G.; Acierno, C.; Rinaldi, L.; Marrone, A.; Salvatore, T.; Monda, M.; Sardu, C.; Marfella, R.; Sasso, F. C.
Modern Challenges in Type 2 Diabetes: Balancing New Medications with Multifactorial Care
2024-01-01 Caturano, A.; Galiero, R.; Rocco, M.; Tagliaferri, G.; Piacevole, A.; Nilo, D.; Di Lorenzo, G.; Sardu, C.; Vetrano, E.; Monda, M.; Marfella, R.; Rinaldi, L.; Sasso, F. C.
Does a strict glycemic control during acute coronary syndrome play a cardioprotective effect? Pathophysiology and clinical evidence
2021-01-01 Caturano, A.; Galiero, R.; Pafundi, P. C.; Cesaro, A.; Vetrano, E.; Palmiero, G.; Rinaldi, L.; Salvatore, T.; Marfella, R.; Sardu, C.; Moscarella, E.; Gragnano, F.; Calabro, P.; Sasso, F. C.
New Advances in Cardiovascular Drugs: A Celebration of the 90th Birthday of Professor Akira Endo
2024-01-01 Caturano, A.
Sodium–Glucose Cotransporter 2 Inhibitors in Patients with Diabetes and Coronary Artery Disease: Translating the Benefits of the Molecular Mechanisms of Gliflozins into Clinical Practice
2023-01-01 Cesaro, A.; Acerbo, V.; Vetrano, E.; Signore, G.; Scherillo, G.; Rotolo, F. P.; De Michele, G.; Scialla, F.; Raucci, G.; Panico, D.; Gragnano, F.; Moscarella, E.; Galiero, R.; Caturano, A.; Ruggiero, R.; Sasso, F. C.; Calabro, P.
Effects of Heart Failure Therapies on Atrial Fibrillation: Biological and Clinical Perspectives
2024-01-01 Mauriello, A.; Ascrizzi, A.; Roma, A. S.; Molinari, R.; Caturano, A.; Imbalzano, E.; D'Andrea, A.; Russo, V.
Non-alcoholic Fatty Liver Disease (NAFLD), Type 2 Diabetes, and Non-viral Hepatocarcinoma: Pathophysiological Mechanisms and New Therapeutic Strategies
2023-01-01 Vetrano, E.; Rinaldi, L.; Mormone, A.; Giorgione, C.; Galiero, R.; Caturano, A.; Nevola, R.; Marfella, R.; Sasso, F. C.
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| Pathophysiological mechanisms and clinical evidence of relationship between Nonalcoholic fatty liver disease (NAFLD) and cardiovascular disease | 1-gen-2021 | Caturano, A.; Galiero, R.; Vetrano, E.; Cesaro, A.; Rinaldi, L.; Salvatore, T.; Marfella, R.; Sardu, C.; Moscarella, E.; Gragnano, F.; Calabro, P.; Sasso, F. C. | |
| The Diabetic Cardiomyopathy: The Contributing Pathophysiological Mechanisms | 1-gen-2021 | Salvatore, T.; Pafundi, P. C.; Galiero, R.; Albanese, G.; Di Martino, A.; Caturano, A.; Vetrano, E.; Rinaldi, L.; Sasso, F. C. | |
| The prognostic role of interatrial block among COVID-19 patients hospitalized in medicine wards | 1-gen-2022 | Russo, V.; Albani, S.; Caturano, A.; Weisz, S. H.; Parisi, V.; Conte, M.; Zaccaro, L.; D'Andrea, A.; Al-Turky, A.; Marchel, M.; Marano, M.; Sasso, F. C.; Attena, E. | |
| Diabetic Gastroparesis: Navigating Pathophysiology and Nutritional Interventions | 1-gen-2024 | Caturano, A.; Cavallo, M.; Nilo, D.; Vaudo, G.; Russo, V.; Galiero, R.; Rinaldi, L.; Marfella, R.; Monda, M.; Luca, G.; Sasso, F. C. | |
| Polypharmacy and Major Adverse Events in Atrial Fibrillation | 1-gen-2022 | Caturano, A.; Spiezia, S.; Brunelli, V.; Galiero, R.; Sasso, F. C. | |
| Pharmacogenomics of Cardiovascular Drugs for Atherothrombotic, Thromboembolic and Atherosclerotic Risk | 1-gen-2023 | Mauriello, A.; Ascrizzi, A.; Molinari, R.; Falco, L.; Caturano, A.; D'Andrea, A.; Russo, V. | |
| Can metformin exert as an active drug on endothelial dysfunction in diabetic subjects? | 1-gen-2021 | Salvatore, T.; Pafundi, P. C.; Galiero, R.; Rinaldi, L.; Caturano, A.; Vetrano, E.; Aprea, C.; Albanese, G.; Di Martino, A.; Ricozzi, C.; Imbriani, S.; Sasso, F. C. | |
| An Overview of the Cardiorenal Protective Mechanisms of SGLT2 Inhibitors | 1-gen-2022 | Salvatore, T.; Galiero, R.; Caturano, A.; Rinaldi, L.; Di Martino, A.; Albanese, G.; Di Salvo, J.; Epifani, R.; Marfella, R.; Docimo, G.; Lettieri, M.; Sardu, C.; Carlo Sasso, F. | |
| Impact of sglt2 inhibitors on heart failure: From pathophysiology to clinical effects | 1-gen-2021 | Palmiero, G.; Cesaro, A.; Vetrano, E.; Pafundi, P. C.; Galiero, R.; Caturano, A.; Moscarella, E.; Gragnano, F.; Salvatore, T.; Rinaldi, L.; Calabro, P.; Sasso, F. C. | |
| Dysregulated Epicardial Adipose Tissue as a Risk Factor and Potential Therapeutic Target of Heart Failure with Preserved Ejection Fraction in Diabetes | 1-gen-2022 | Salvatore, T.; Galiero, R.; Caturano, A.; Vetrano, E.; Rinaldi, L.; Coviello, F.; Di Martino, A.; Albanese, G.; Colantuoni, S.; Medicamento, G.; Marfella, R.; Sardu, C.; Sasso, F. C. | |
| Comment on: Prevalence of micro and macro vascular complications and their risk factors in type 2 diabetes in saudi arabian population: An analysis from shis | 1-gen-2021 | Caturano, A.; Mercadante, S.; Mariniello, A.; Esposito, F.; Galiero, R.; Brunelli, V. | |
| Cardiac Hypertrophy: From Pathophysiological Mechanisms to Heart Failure Development | 1-gen-2022 | Caturano, A.; Vetrano, E.; Galiero, R.; Salvatore, T.; Docimo, G.; Epifani, R.; Alfano, M.; Sardu, C.; Marfella, R.; Rinaldi, L.; Sasso, F. C. | |
| The Significance of Statin-Associated Muscle Symptoms and Its Impact on Patient Adherence and Outcomes | 1-gen-2023 | Caturano, A.; Albanese, G.; Di Martino, A.; Galiero, R.; Sasso, F. C. | |
| Effects of a Combination of Empagliflozin Plus Metformin vs. Metformin Monotherapy on NAFLD Progression in Type 2 Diabetes: The IMAGIN Pilot Study | 1-gen-2023 | Caturano, A.; Galiero, R.; Loffredo, G.; Vetrano, E.; Medicamento, G.; Acierno, C.; Rinaldi, L.; Marrone, A.; Salvatore, T.; Monda, M.; Sardu, C.; Marfella, R.; Sasso, F. C. | |
| Modern Challenges in Type 2 Diabetes: Balancing New Medications with Multifactorial Care | 1-gen-2024 | Caturano, A.; Galiero, R.; Rocco, M.; Tagliaferri, G.; Piacevole, A.; Nilo, D.; Di Lorenzo, G.; Sardu, C.; Vetrano, E.; Monda, M.; Marfella, R.; Rinaldi, L.; Sasso, F. C. | |
| Does a strict glycemic control during acute coronary syndrome play a cardioprotective effect? Pathophysiology and clinical evidence | 1-gen-2021 | Caturano, A.; Galiero, R.; Pafundi, P. C.; Cesaro, A.; Vetrano, E.; Palmiero, G.; Rinaldi, L.; Salvatore, T.; Marfella, R.; Sardu, C.; Moscarella, E.; Gragnano, F.; Calabro, P.; Sasso, F. C. | |
| New Advances in Cardiovascular Drugs: A Celebration of the 90th Birthday of Professor Akira Endo | 1-gen-2024 | Caturano, A. | |
| Sodium–Glucose Cotransporter 2 Inhibitors in Patients with Diabetes and Coronary Artery Disease: Translating the Benefits of the Molecular Mechanisms of Gliflozins into Clinical Practice | 1-gen-2023 | Cesaro, A.; Acerbo, V.; Vetrano, E.; Signore, G.; Scherillo, G.; Rotolo, F. P.; De Michele, G.; Scialla, F.; Raucci, G.; Panico, D.; Gragnano, F.; Moscarella, E.; Galiero, R.; Caturano, A.; Ruggiero, R.; Sasso, F. C.; Calabro, P. | |
| Effects of Heart Failure Therapies on Atrial Fibrillation: Biological and Clinical Perspectives | 1-gen-2024 | Mauriello, A.; Ascrizzi, A.; Roma, A. S.; Molinari, R.; Caturano, A.; Imbalzano, E.; D'Andrea, A.; Russo, V. | |
| Non-alcoholic Fatty Liver Disease (NAFLD), Type 2 Diabetes, and Non-viral Hepatocarcinoma: Pathophysiological Mechanisms and New Therapeutic Strategies | 1-gen-2023 | Vetrano, E.; Rinaldi, L.; Mormone, A.; Giorgione, C.; Galiero, R.; Caturano, A.; Nevola, R.; Marfella, R.; Sasso, F. C. |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile
Scopri
Tipologia
- 1 Contributo su Rivista6178
Data di pubblicazione
- In corso di stampa8
- 2020 - 20251867
- 2010 - 20192542
- 2000 - 20091165
- 1990 - 1999383
- 1980 - 1989186
- 1971 - 197927
Rivista
- NUTRIENTS77
- MOVEMENT DISORDERS75
- INTERNATIONAL JOURNAL OF MOLECULA...73
- PLOS ONE72
- M.L.T.J. MUSCLES, LIGAMENTS AND T...68
- INTERNATIONAL JOURNAL OF ENVIRONM...56
- INTERNATIONAL JOURNAL OF CARDIOLOGY46
- SCIENTIFIC REPORTS43
- ANTICANCER RESEARCH42
- NEUROLOGICAL SCIENCES41
Serie
- RECENT RESULTS IN CANCER RESEARCH1
Keyword
- Humans245
- Male120
- Female100
- Animals83
- inflammation68
- Adult62
- COVID-1958
- Middle Aged57
- obesity48
- Aged47
Lingua
- eng4317
- ita488
- und29
- spa6
- fre5
- ger3
- por1
Accesso al fulltext
- no fulltext6032
- reserved105
- open40
- embargoed1